Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
111. |
ECCT/24/06/06 | EDE Scanner Study A non-interventional clinical validation study of the Exponential Deep Examination (EDE) scanner in the detection of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria. |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Tina 3. VIDELIS NDUBA Site(s) in Kenya 1. VICTORIA BIOMEDICAL RESEARCH INSTITUTE (Kisumu county) 2. KEMRI/CRDR Siaya Clinical Trials Annex (Siaya county) 3. Ahero Clinical Trials Unit (Kisumu county) |
20-01-2025 |
View |
112. |
ECCT/24/06/05 | SII-qHPV Vaccine Study A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years. |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) 2. KEMRI - CCR Nairobi (Nairobi City county) |
26-11-2024 |
View |
113. |
ECCT/24/06/04 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N) (Machakos county) |
23-10-2024 |
View |
114. |
ECCT/24/06/03 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Walter Otieno Site(s) in Kenya 1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county) |
20-09-2024 |
View |
115. |
ECCT/24/06/02 | ALNASA A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Jesse Gitaka Site(s) in Kenya 1. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 2. Clinical Research Health Network (CREA-N) (Machakos county) 3. KEMRI-Mtwapa Clinical Annex (Kilifi county) 4. University of Nairobi Clinical Research Centre (Nairobi City county) 5. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
25-11-2024 |
View |
116. |
ECCT/24/06/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Raymond Scott McClelland Site(s) in Kenya 1. Pwani Research Centre (Mombasa county) |
02-07-2024 |
View |
117. |
ECCT/24/05/06 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) - Kisumu (Kisumu county) |
27-05-2024 |
View |
118. |
ECCT/24/05/05 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Kariuki Simon Kariuki 2. Patricia Odero Ojwang Site(s) in Kenya 1. Kenya Medical Research Institute-Dr Kariuki (Kisumu county) |
29-08-2024 |
View |
119. |
ECCT/24/05/03 | SIBP-MMR-02 A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age |
Principal Investigator(s) 1. Dr Walter Otieno 2. Dr. Diana Odhiambo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. Victoria Biomedical Research Institute (Kisumu county) |
27-05-2024 |
View |
120. |
ECCT/24/05/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county) |
08-05-2024 |
View |